Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports ’08 net loss from ImClone deal and Zyprexa settlement
You may also be interested in...
Mega-Merger Could Usher In New Era Of Consolidation
Given the looming patent cliff facing drug manufacturers and the lack of new products coming out of R&D to replace lost sales, it's hardly surprising that murmurings of industry consolidation are swirling
Mega-Merger Could Usher In New Era Of Consolidation
Given the looming patent cliff facing drug manufacturers and the lack of new products coming out of R&D to replace lost sales, it's hardly surprising that murmurings of industry consolidation are swirling
Lilly’s Zyprexa Off-Label Settlement: Record Fine, Routine Compliance Deal
Lilly agreed to pay $1.4 billion in criminal and civil fines and pled guilty to misbranding its antipsychotic drug Zyprexa in a settlement with the U.S. Department of Justice. Despite the record-breaking sum, however, the terms in the accompanying corporate integrity agreement are similar to previous CIAs